Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19414235 | 0.92 | GAA (0.54) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL29196492 | 0.87 | POLB (0.61) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL10525359 | 0.87 | POLB (0.59) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL6790228 | 0.86 | ALDH1A1 (0.51) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL1287360 | 0.86 | ALDH1A1 (0.51) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL1287379 | 0.86 | MEN1 (0.52) | GAAPOLBKMT2AALDH1A1MEN1 | |
| SCHEMBL8738156 | 0.82 | EZH2 (0.76) | POLBEZH2KMT2AMEN1L3MBTL1 | |
| SCHEMBL6789098 | 0.81 | GAA (0.43) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL11317525 | 0.81 | LMNA (0.67) | GAAPOLBEZH2KMT2AALDH1A1 | |
| SCHEMBL3295977 | 0.80 | RECQL (0.57) | GAAPOLBEZH2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021056105-A1 | COMPOSITIONS AND METHODS BASED ON HIV GP120 MUTANTS | CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) | 2021-04-01 | — | — | WO | disclosed |
| US-9975848-B2 | Inhibitors of HIV-1 entry and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-22 | — | — | US | disclosed |
| US-9776963-B2 | Small molecule CD4 mimetics and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | BRYN MAWR COLLEGE | 2017-08-17 | — | — | US | disclosed |
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| WO-2016025681-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
| WO-2013090696-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-8361969-B2 | Designer cyclic peptides—HIV gp120 antagonists and their applications | CZYRYCA PRZEMYSLAW (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120270806-A1 | Designer Cyclic Peptides - HIV gp120 Antagonists and their Applications | CZYRYCA PRZEMYSLAW (US) | 2012-10-25 | — | — | US | disclosed |
| US-20110195083-A1 | CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2011-08-11 | — | — | US | disclosed |
| WO-2010053583-A2 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA FARBER CANCER INSTITUTE (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | GAA 2735/4885POLB 2974/4885EZH2 4808/4885 |
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD81, ICAM1 | GAA 1820/4885POLB 1622/4885EZH2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.